 Second-Quarter 2021 Results and Highlights: Consolidated revenue increased 40 to 122 million Clinical Services revenue increased 37 to 101 million Pharma Services revenue increased 55 to 20 million Completed the acquisitions of Trapelo Health in April and Inivata Limited in June FORT MYERS, FL ACCESSWIRE August 6, 2021 NeoGenomics, Inc. NASDAQ:NEO the Company, a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2021. Second-quarter results were strong as all three of our divisions grew significantly year-over-year. 